[ad_1]
The new corona vaccine developed by China’s state group Sinopharm (Sinopharm) triggered a “serious adverse event.” The Peruvian subjects developed a rare neurological disease that causes arm movement. The Peruvian authorities announced the temporary suspension of the Sinopharm clinical trial. proof.
According to reports from Reuters and Agence France-Presse, the Peruvian Ministry of Health announced yesterday that there was a “serious adverse event” in the clinical trial of Continental Sinopharm’s new corona vaccine, and the authorities have decided to temporarily suspend the clinical trial of the Sinopharm vaccine.
According to local media reports in Peru, the National Institute of Health (INS) of Peru stated on the 11th that a volunteer who participated in the clinical trial of the Sinopharm vaccine developed symptoms of difficulty in the arm and therefore suspended the experiment. German Malaga, principal investigator for the National Institutes of Health of Peru, said that a volunteer developed neurological symptoms that may be equivalent to Guillain-Barré syndrome.
Guillain-Barré syndrome is a rare but not contagious disease that mainly affects the movement of the limbs, arms and legs of patients. According to the official website of the Centers for Disease Control and Prevention (CDC), “Guillain-Barré syndrome” is a rare disease in which the patient’s own immune system damages the nerves, causing muscle weakness and even paralysis. In the 1970s, there were cases of people suffering from “Guillain-Barré syndrome” after being vaccinated against African swine fever. However, follow-up studies indicated that cases of “Guillain-Barré syndrome” due to the vaccine were still rare.
The Peruvian Health Ministry said the current adverse event has been investigated to determine if it is related to vaccination or if there are other factors.
Approximately 12,000 volunteers participated in the clinical trial of the new corona vaccine conducted by Continental Sinopharm Group in Peru, with the trial originally expected to be completed next week. If the vaccine is finally developed successfully, the Peruvian government hopes to purchase 20 million doses of the national medicine vaccine to vaccinate two-thirds of the country’s population.
Including volunteers from Argentina, Russia and Saudi Arabia, more than 60,000 people around the world have been vaccinated against the national medicine.
Peru’s new crown epidemic is severe, and it is one of the countries with the highest mortality rate for new crowns in the world. According to the global epidemic statistics from Johns Hopkins University in the United States, at 1:00 p.m. on the 13th, the number of infected people in Peru is around 980,000. The death toll exceeded 36,000.
(Zhongshi News Network)
[ad_2]
